Hanmi Pharm Co Ltd

ESG Report

Report overview

The report describes Hanmi Pharm's 2023 sustainability performance across its consolidated environmental and social scope. The company reports record consolidated sales of KRW 1.4909 trillion and discloses Scope 1, Scope 2 and Scope 3 emissions. It identifies double materiality as the basis for its sustainability-topic assessment. The report also presents a Scope 1 and Scope 2 reduction roadmap targeting a 30% reduction by 2030 and Net Zero by 2040.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Publication date: 1 May 2024
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Scope 3 emissions
Energy consumption
Water consumption
Waste
Employees
Women on the board
Women in management
Workplace fatalities
Net zero target

Materiality

Assessment
Basis
Matrix

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services